|
Approve Suite Weekly · Wednesday, October 7, 2026 · read online
8-K: ROCKET PHARMACEUTICALS, INC. mentions clinical hold
Rocket Pharmaceuticals' RP-A501 program placed on clinical hold. A clinical hold stops all clinical activity for a program and triggers material reporting obligations under the company's loan agreements. This signals potential safety or CMC concerns that the FDA determined warrant cessation of the trial. DesBio warned for marketing unapproved OTC drugs for sexually transmitted infections. The warning letter identifies unapproved drug products being sold directly to consumers, creating public health risk by potentially delaying appropriate medical care and enabling disease transmission. This signals FDA enforcement against unlicensed OTC drug marketing in a sensitive therapeutic area. The pattern? Warning letters led the week with 19, ahead of trial status changes (13), out of 52 counted.
This week's author: Ryan Burke, Approve Suite
8-K: ROCKET PHARMACEUTICALS, INC. mentions clinical hold
8-K · Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals' RP-A501 program placed on clinical hold.
Why it matters. A clinical hold stops all clinical activity for a program and triggers material reporting obligations under the company's loan agreements. This signals potential safety or CMC concerns that the FDA determined warrant cessation of the trial.
What to watch. Items 1.01, 2.02 and 8.01 carry the material terms; the exhibits hold the detail.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Warning letter: DesBio/Deseret Biologicals, Inc. — Unapproved New Drugs
Warning letter · DesBio/Deseret Biologicals, Inc.
DesBio warned for marketing unapproved OTC drugs for sexually transmitted infections.
Why it matters. The warning letter identifies unapproved drug products being sold directly to consumers, creating public health risk by potentially delaying appropriate medical care and enabling disease transmission. This signals FDA enforcement against unlicensed OTC drug marketing in a sensitive therapeutic area.
What to watch. The firm's written response is due in 15 working days; FDA posts a close-out letter only after it verifies the corrections.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
Final rule
FDA exempts certain Class II clinical toxicology test systems from 510(k) premarket notification.
Why it matters. This final rule reduces regulatory burden on device manufacturers by eliminating 510(k) submission requirements for specified clinical toxicology test systems. The exemption reflects FDA's determination that premarket notification is not necessary for these devices to ensure safety and effectiveness.
What to watch. The amended text appears in the eCFR on the effective date; procedures that cite the section are the ones affected.
READ MORE → · open in Approve Suite
By the numbers
Inspections: 0 NAI · 0 VAI · 0 OAI Warning letters: 19 Class I recalls: 0 (Class II 0, Class III 0) Trial stops and status changes: 13 (results posted: 5) Raises: 8, $530M disclosed
88 events, down 63% on the prior 7 days.
203 listed companies report under 12 months of runway.
Signals
1. Warning letter: OrganiCare, LLC / OrganiCare Nature’s Science, LLC — Unapproved New Drugs Warning letter · OrganiCare, LLC app 2. Warning letter: Bioactive Services USA, LLC / Herstat Inc. — Unapproved New Drugs Warning letter · Bioactive Services USA, LLC / Herstat Inc. app 3. 8-K: CERO THERAPEUTICS HOLDINGS, INC. mentions clinical hold 8-K · CERo Therapeutics Holdings, Inc. app 4. 8-K: Turn Therapeutics Inc. mentions topline results 8-K · Turn Therapeutics app 5. Approved: NDA 219617 — Ever Valinject, NDA 219617 Approval · Ever Valinject app 6. Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System Final rule app
Why this exists
Approve Suite Weekly exists so a QA or RA lead can read one email on Tuesday and know what FDA, the SEC and ClinicalTrials.gov published in the past week. Every line links to its public source; nothing here is advice.
Sponsor this email
How was this week's email?
AwesomeDecentNot great
| 